|
[1] CZAJA AJ. Review article:Iron disturbances in chronic liver diseases other than haemochromatosis-pathogenic, prognostic, and therapeutic implications[J]. Aliment Pharmacol Ther, 2019, 49 (6) :681-701.
|
|
[2] European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis[J]. J Hepatol, 2010, 53 (1) :3-22.
|
|
[3] BACON BR, ADAMS PC, KOWDLEY KV, et al. Diagnosis and management of hemochromatosis:2011 practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology, 2011, 54 (1) :328-343.
|
|
[4] FITZSIMONS EJ, CULLIS JO, THOMAS DW, et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017update) [J]. Br J Haematol, 2018, 181 (3) :293-303.
|
|
[5] VANCLOOSTER A, CASSIMAN D, van STEENBERGEN W, et al. The quality of hereditary haemochromatosis guidelines:A comparative analysis[J]. Clin Res Hepatol Gastroenterol, 2015, 39 (2) :205-214.
|
|
[6] SIMON M, BOUREL M, FAUCHET R, et al. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis[J]. Gut, 1976, 17 (5) :332-334.
|
|
[7] CARTWRIGHT GE, EDWARDS CQ, KRAVITZ K, et al. Hereditary hemochromatosis. Phenotypic expression of the disease[J]. N Engl J Med, 1979, 301 (4) :175-179.
|
|
[8] FEDER JN, GNIRKE A, THOMAS W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis[J]. Nat Genet, 1996, 13 (4) :399-408.
|
|
[9] KANWAR P, KOWDLEY KV. Diagnosis and treatment of hereditary hemochromatosis:An update[J]. Expert Rev Gastroenterol Hepatol, 2013, 7 (6) :517-530.
|
|
[10] ADAMS PC. Epidemiology and diagnostic testing for hemochromatosis and iron overload[J]. Int J Lab Hematol, 2015, 37 (Suppl 1) :25-30.
|
|
[11] DEUGNIER Y, MORCET J, LAINF, et al. Reduced phenotypic expression in genetic hemochromatosis with time:Role of exposure to non-genetic modifiers[J]. J Hepatol, 2019, 70 (1) :118-125.
|
|
[12] WANG Y, DU Y, LIU G, et al. Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis[J]. Int J Hematol, 2017, 105 (4) :521-525.
|
|
[13] LV T, ZHANG W, XU A, et al. Non-HFE mutations in haemochromatosis in China:Combination of heterozygous mutations involving HJV signal peptide variants[J]. J Med Genet, 2018, 55 (10) :650-660.
|
|
[14] ZHANG W, LV T, HUANG J, et al. Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1gene:A case report and a review of the literature[J]. Medicine (Baltimore) , 2017, 96 (38) :e8064.
|
|
[15] TSUI WM, LAM PW, LEE KC, et al. The C282Y mutation of the HFE gene is not found in Chinese haemochromatotic patients:Multicentre retrospective study[J]. Hong Kong Med J, 2000, 6 (2) :153-158.
|
|
[16] YE K, CAO C, LIN X, et al. Natural selection on HFE in Asian populations contributes to enhanced non-heme iron absorption[J]. BMC Genet, 2015, 16:61.
|
|
[17] ROETTO A, TOTARO A, CAZZOLA M, et al. Juvenile hemochromatosis locus maps to chromosome 1q[J]. Am J Hum Genet, 1999, 64 (5) :1388-1393.
|
|
[18] PAPANIKOLAOU G, PAPAIOANNOU M, POLITOU M, et al.Genetic heterogeneity underlies juvenile hemochromatosis phenotype:Analysis of three families of northern Greek origin[J]. Blood Cells Mol Dis, 2002, 29 (2) :168-173.
|
|
[19] PAPANIKOLAOU G, SAMUELS ME, LUDWIG EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis[J]. Nat Genet, 2004, 36 (1) :77-82.
|
|
[20] BABITT JL, HUANG FW, WRIGHTING DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression[J]. Nat Genet, 2006, 38 (5) :531-539.
|
|
[21] ROETTO A, PAPANIKOLAOU G, POLITOU M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis[J]. Nat Genet, 2003, 33 (1) :21-22.
|
|
[22] ZUMERLE S, MATHIEU JR, DELGA S, et al. Targeted disruption of hepcidin in the liver recapitulates the hemochromatotic phenotype[J]. Blood, 2014, 123 (23) :3646-3650.
|
|
[23] CAMASCHELLA C, ROETTO A, CALA, et al. The gene TFR2is mutated in a new type of haemochromatosis mapping to7q22[J]. Nat Genet, 2000, 25 (1) :14-15.
|
|
[24] PIETRANGELO A, CALEFFI A, HENRION J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes[J]. Gastroenterology, 2005, 128 (2) :470-479.
|
|
[25] CORRADINI E, ROZIER M, MEYNARD D, et al. Iron regulation of hepcidin despite attenuated Smad1, 5, 8 signaling in mice without transferrin receptor 2 or Hfe[J]. Gastroenterology, 2011, 141 (5) :1907-1914.
|
|
[26] ZHANG W, XU A, LI Y, et al. A novel SLC40A1 p. Y333H mutation with gain of function of ferroportin:A recurrent cause of haemochromatosis in China[J]. Liver Int, 2019, 39 (6) :1120-1127.
|
|
[27] PIETRANGELO A. Ferroportin disease:Pathogenesis, diagnosis and treatment[J]. Haematologica, 2017, 102 (12) :1972-1984.
|
|
[28] NJAJOU OT, VAESSEN N, JOOSSE M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis[J]. Nat Genet, 2001, 28 (3) :213-214.
|
|
[29] SHAM RL, PHATAK PD, WEST C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features[J]. Blood Cells Mol Dis, 2005, 34 (2) :157-161.
|
|
[30] ALTAMURA S, KESSLER R, GRNE HJ, et al. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload[J]. Cell Metab, 2014, 20 (2) :359-367.
|
|
[31] CHEN SR, YANG LQ, CHONG YT, et al. Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4[J]. Intern Med J, 2015, 45 (6) :672-676.
|
|
[32] PIETRANGELO A, MONTOSI G, TOTARO A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene[J]. N Engl J Med, 1999, 341 (10) :725-732.
|
|
[33] MONTOSI G, DONOVAN A, TOTARO A, et al. Autosomaldominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene[J]. J Clin Invest, 2001, 108 (4) :619-623.
|
|
[34] ZOHN IE, de DOMENICO I, POLLOCK A, et al. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease[J]. Blood, 2007, 109 (10) :4174-4180.
|
|
[35] LE LAN C, MOSSER A, ROPERT M, et al. Sex and acquired cofactors determine phenotypes of ferroportin disease[J].Gastroenterology, 2011, 140 (4) :1199-1207.
|
|
[36] KONO S. Aceruloplasminemia:An update[J]. Int Rev Neurobiol, 2013, 110:125-151.
|
|
[37] MIYAJIMA H, NISHIMURA Y, MIZOGUCHI K, et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration[J]. Neurology, 1987, 37 (5) :761-767.
|
|
[38] HARRIS ZL, TAKAHASHI Y, MIYAJIMA H, et al. Aceruloplasminemia:Molecular characterization of this disorder of iron metabolism[J]. Proc Natl Acad Sci U S A, 1995, 92 (7) :2539-2543.
|
|
[39] XU W, ZHI Y, YUAN Y, et al. Correlations between abnormal iron metabolism and non-motor symptoms in Parkinson's disease[J]. J Neural Transm (Vienna) , 2018, 125 (7) :1027-1032.
|
|
[40] LI XH, LU Y, LING Y, et al. Clinical and molecular characterization of Wilson's disease in China:Identification of 14 novel mutations[J]. BMC Med Genet, 2011, 12:6.
|
|
[41] HAYASHI A, WADA Y, SUZUKI T, et al. Studies on familial hypotransferrinemia:Unique clinical course and molecular pathology[J]. Am J Hum Genet, 1993, 53 (1) :201-213.
|
|
[42] HEILMEYER L, KELLER W, VIVELL O, et al. Congenital atransferrinemia in a 7-year-old girl[J]. Dtsch Med Wochenschr, 1961, 86:1745-1751.
|
|
[43] ATHIYARATH R, ARORA N, FUSTER F, et al. Two novel missense mutations in iron transport protein transferrin causing hypochromic microcytic anaemia and haemosiderosis:Molecular characterization and structural implications[J]. Br J Haematol, 2013, 163 (3) :404-407.
|
|
[44] CHEN C, WEN S, TAN X. Molecular analysis of a novel case of congenital atransferrinemia[J]. Acta Haematol, 2009, 122 (1) :27-28.
|
|
[45] YACHIE A, NIIDA Y, WADA T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1deficiency[J]. J Clin Invest, 1999, 103 (1) :129-135.
|
|
[46] RADHAKRISHNAN N, YADAV SP, SACHDEVA A, et al. Human heme oxygenase-1 deficiency presenting with hemolysis, nephritis, and asplenia[J]. J Pediatr Hematol Oncol, 2011, 33 (1) :74-78.
|
|
[47] BHUVA M, SEN S, ELSEY T, et al. Sequence analysis of exon1 of the ferritin light chain (FTL) gene can reveal the rare disorder‘hereditary hyperferritinaemia without cataracts’[J]. Br J Haematol, 2019, 184 (6) :1037-1040.
|
|
[48] FERRO E, CAPRA AP, ZIRILLI G, et al. FTL c.-168G>C mutation in hereditary hyperferritinemia cataract syndrome:A new Italian family[J]. Pediatr Dev Pathol, 2018, 21 (5) :456-460.
|
|
[49] MATTILA RM, SAINIO A, JRVELINEN M, et al. A novel double nucleotide variant in the ferritin-L iron-responsive element in a Finnish patient with hereditary hyperferritinaemia-cataract syndrome[J]. Acta Ophthalmol, 2018, 96 (1) :95-99.
|
|
[50] YIN D, KULHALLI V, WALKER AP. Raised serum ferritin concentration in hereditary hyperferritinemia cataract syndrome is not a marker for iron overload[J]. Hepatology, 2014, 59 (3) :1204-1206.
|
|
[51] KATO J, FUJIKAWA K, KANDA M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload[J]. Am J Hum Genet, 2001, 69 (1) :191-197.
|
|
[52] DAHER R, KANNENGIESSER C, HOUAMEL D, et al. Heterozygous mutations in BMP6 pro-peptide lead to inappropriate hepcidin synthesis and moderate iron overload in humans[J].Gastroenterology, 2016, 150 (3) :672-683.
|
|
[53] LE GAC G, GOURLAOUEN I, KA C, et al. The p. Leu96Pro missense mutation in the BMP6 gene is repeatedly associated with hyperferritinemia in patients of French origin[J]. Gastroenterology, 2016, 151 (4) :769-770.
|
|
[54] PIUBELLI C, CASTAGNA A, MARCHI G, et al. Identification of new BMP6 pro-peptide mutations in patients with iron overload[J]. Am J Hematol, 2017, 92 (6) :562-568.
|
|
[55] McDONALD CJ, RISHI G, SECONDES ES, et al. Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading[J]. Hum Genomics, 2018, 12 (1) :23.
|
|
[56] BARTON JC. Hemochromatosis and iron overload:From bench to clinic[J]. Am J Med Sci, 2013, 346 (5) :403-412.
|
|
[57] OLYNYK JK, CULLEN DJ, AQUILIA S, et al. A populationbased study of the clinical expression of the hemochromatosis gene[J]. N Engl J Med, 1999, 341 (10) :718-724.
|
|
[58] HAYASHI H, WAKUSAWA S, MOTONISHI S, et al. Genetic background of primary iron overload syndromes in Japan[J].Intern Med, 2006, 45 (20) :1107-1111.
|
DownLoad: